Magneto-nanosensor for sensitive detection of ovarian cancer antibody biomarker anti-Selenium-Binding Protein 1

Autoantibody biomarker relatively recently gains a lot of research interest for early detection of cancer. Cancer autoantibody is an antibody produced by the host's immune system in response to tumor antigen. It is produced at a much earlier disease stage before other biomarkers can be observed, circulates in the serum for a relatively long period of time, and is present at higher concentrations than antigen biomarkers. In addition to identifying the early antibody biomarker, early detection of cancer needs to be complemented by the availability of ultrasensitive and reliable detection platform. Magneto-Nanosensor is a robust biomolecular diagnostics platform that has been shown to have superior sensitivity and dynamic range compared to the current gold standard ELISA (Enzyme-linked Immunosorbent Assay). One potential antibody biomarker for the early detection of ovarian cancer is anti-Selenium-Binding Protein 1 (anti-SBP1, also known as anti-SELENBP1). Studies showed that concentration levels of SBP1 are associated with cancer progression. This submission reports highly-sensitive and reliable detection of anti-SBP1 using magnetic immunoassay technique on Magneto-Nanosensor platform. The high sensitivity of our detection platform combined with the early antibody biomarker can serve as a powerful diagnostic tool for enabling early detection of ovarian cancer.